1			U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.		SERIAL NO.	100 miles	٦
			PATENT AND TRADEMARK OFFICE			T9667		09/885,721		E I
LIST OF PAIOR ART CITE				BY APPLICAN	ar.	APPLICANT John G. Babish, et al				
JAN 3 1 2002						FILING DATE June 20, 2001	GROUB 1614 65	1600/2X	2002	
U.S. PATENT DOCUMENTS										
EXAMINER INITIALS		DOCUMENT NUMBER		DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	3,965,188		06/22/76	Donald H. Westermann, et al.				z	
	AB	4,767,640		08/30/88	Henry Goldstein, et al.					
	AC	5,155,276		10/13/92	Herbert Paul					
	AD	5,387,425		- 02/07/95	Wen P. Hsu, et al					
	AE	5,827,895		10/27/98	Louise Nutter, et al.					
	AF	6,129,907		10/10/2000	Prom K. Sreenivasan, et al					
	AG									
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER		DATE		COUNTRY		SUBCLASS	TRANSLATION YES NO	
	-AM	WO 00/68356		16/11/2000	PCT					
	AN				ļ					
OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.										
/	AR Tobe, H. et al. 1997. Bone Resorption Inhibitors from hop Extract. Biosci. Biotech. Biochem 61(1)158-159									
	AS	Yamamoto, K. 2000. Suppression of Cyclooxygenase-2 Gene Transcription by Humaion of Beer hop extract studied with Reference to Glucocorticoid. FEBS Letters 465:103-106.								
,	Lopes Vaz, A., Double-blind Clinical Evaluation of the Relative Efficacy of Ibuprofen and Glucosamine sulphate in the management of osteoarthritis of the knee in Outpatients, 8 Curr. Med Res Opin. 145-149 (1982).									
	AU The Ability of a Test Material to Inhibit COX synthesis of PGE2 was determined essentially as described by Noreen, Y., et al. (L. Nat. Prod. 61, 2-7, 1998).									
AV Hamberg, M. and Samuelsson, B. (J. Biol. Chem. 1971. 246, 6713-6721)										,
	AW Median Effect Methods described by T-C Chou and P. Talaly (Trends Pharmacol. Sci. 4:450-454).									
11nd is a										
EXAMINER MALE CONSIDERED SIGNO										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										